Jade Biosciences, Inc. JBIO
14.42
(0.31)
(2.10%)
as of 25 Sep
- Market cap
- $936.8M
- P/E
- 0.0×
Follow JBIO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
14.93 | 14.29 | 21.09 | 9.01 |
+8 more quarters Free account |
Net Debt/EBITDA |
7.78 | 7.09 | 9.45 | 7.22 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.60 | 7.22 | 0.88 | |
Capex/Depreciation |
0.00 | 0.00 | 0.01 | 0.35 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.72) | (0.42) | (1.07) | (0.56) | |
Cash per Share |
7.55 | 5.39 | 10.72 | 5.02 | |
Shareholders Equity per Share |
7.21 | 5.13 | 10.60 | 4.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.21 | 5.13 | 10.60 | 4.53 | |
Free Cash Flow |
(43.66) | (24.08) | (33.65) | (22.18) | |
Working Capital |
439.68 | 296.23 | 332.28 | 179.00 | |
Capital Expenditures |
— | — | 0.00 | (0.06) | |
Net Current Asset Value |
439.05 | 295.55 | 331.55 | 178.26 | |
| Other line items | |||||
Quick Ratio |
14.61 | 13.96 | 20.33 | 8.90 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.72) | (0.42) | (1.07) | (0.56) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
7.08 | 2.02 | 1.72 | 1.13 | |
Average Assets |
348.04 | 198.48 | 211.29 | 146.70 | |
Average Common Equity |
320.73 | 185.75 | 142.86 | 129.92 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates